Summary:
A randomized phase 2A, double-blind, placebo-controlled study of the efficacy and safety of CP-601,927 augmentation of antidepressant therapy in major depression.
Qualified Participants Must:
• Be 18 to 65 years of age
•
Have a primary current diagnosis of MDD (Major Depressive Disorder)
•
Be a non-smoker
•
Be on an antidepressant and not have a full response to the medication
•
Be physically healthy
Qualified Participants May Receive:
Doctor visits, study medication, study evaluations, and compensation for time and travel.